Singapore markets open in 3 hours 24 minutes

Vyant Bio, Inc. (VYNT)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1700+0.0030 (+1.80%)
At close: 12:20PM EDT

Vyant Bio, Inc.

2 Executive Campus
2370 State Route 70 Suite 310
Cherry Hill, NJ 08002
United States
201 479 1357

Full-time employees4

Key executives

NameTitlePayExercisedYear born
Mr. Andrew D.C. LaFrence CPA, CPAPres, CEO & CFO407.4kN/A1963
Mr. Yung-Ping Yeh M.B.A., M.S., P.M.P.Co-Founder & Director22.5kN/A1976
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.

Corporate governance

Vyant Bio, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.